Cardio-K

Cardio-K

Out of Stock
Quantity
£7.99
Buy 2 and save £2.00
Buy 3 and save £5.00
Buy 4 and save £7.00

30 Capsules

Cardio-K is a food supplement with approved claims to help maintain normal LDL cholesterol concentration by EFSA (European Food Safety Authority).

Clinical studies have shown the effects of red yeast rice preparations with a known 10mg Monacolin K content reduce both LDL concentrations and also total cholesterol levels.

The European Food Safety Authority has recently approved Monacolin K (nature's statin) as an ingredient that can help maintain normal LDL cholesterol levels.

Monacolins are naturally occurring substances found in Red Yeast Rice, however, it is Monacolin K that is the active ingredient that works in a very similar way to some pharmaceutical grade statins, and the big difference being it is naturally present not chemically manufactured.

Red Yeast Rice is made by fermenting a type of red yeast called Monascus Purpureus over rice.

Several studies have shown good evidence that Monacolin K present in red yeast rice can significantly lower total and "bad" LDL cholesterol levels.


Two clinical studies recently submitted to the European Food Safety Authority (EFSA) show taking 7.5mg of Monacolin K per day for 12 weeks can reduce LDL levels by up to 22% and taking 11.4mg per day for 8 weeks can reduce LDL by up to 26%.

 

Study 1 - Results after 12 weeks: 
83 subjects with hypercholesterolaemia were tested. 42 subjects in the treatment group receiving a daily dose of around 7.5mg of Monacolin K. 41 subjects in the placebo group received a rice powder. After 12 weeks the results of the treatment group show a reduction from base line of 22% of LDL cholesterol levels with only 3% reduction in the placebo group.

 


Study 2 - Results after 8 weeks:
 

75 subjects with hypercholesterolaemia were tested. 38 subjects in the treatment group receiving a daily dose of around 11.4mg of Monacolin K. 37 subjects in the placebo group received a grounded rice. After 8 weeks the results of the treatment group show a reduction from base line of 26.3% of LDL cholesterol levels with only 1.4% reduction in the placebo group.




View delivery options

View further information